about
Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.Management of neuroendocrine tumors.Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea.Older adults may not consider life expectancy an important factor in cancer screening.Implementation of an integrated computerized prescriber order-entry system for chemotherapy in a multisite safety-net health system.Development and implementation of an interdisciplinary oncology program in a community hospitalImportance of ethnicity and smoking status in EGFR gene testing in lung cancersRestoring the switch for cancer cell death: Targeting the apoptosis signaling pathwayTo do or not to do: A concise update of current clinical controversies in immune checkpoint blockadeDriving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level
P50
Q33413057-15C14C17-7776-44AD-893D-A9C47148F534Q38152887-73072F34-477A-4E02-983A-525FEB3E6911Q38263806-922AEB45-A1F1-4587-A654-32D80D935699Q38304271-1D888879-D6F5-44A7-8524-AB2D1408DC97Q38412163-D4FD3021-3705-472D-B68C-63E61DE26F31Q38666159-B7D09F4C-7460-44D6-BE9E-10BF5EBCAD05Q38792725-85FF3724-97F3-492F-9B9C-7D1039DEA258Q38881168-9DD08C9F-3649-4201-8E2D-FB56A3A5AECFQ38987953-F2F53DA7-FF51-4D9D-84D8-8E7EBB645F62Q49859399-C18F382D-D9EE-4227-A6B2-473FE74F152DQ49859435-E8F6E0CA-4C36-49AA-B3FD-4524DA6948E4Q51742045-2577C607-9467-4419-B2D3-5CE48C5A1C8AQ84863728-8C536BBD-2866-438D-A33A-9FEAC9414AFEQ87114331-44D3D1E0-E5B5-45FC-B770-067220C87BD5Q88669531-6F392058-573B-4B52-AA35-B849456C89B1Q89572119-46EBDCCD-C70B-456E-B120-4C8754CBE188Q92818201-90AD8E1F-73CA-419B-9041-324FBC442111
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Clement Chung
@ast
Clement Chung
@en
Clement Chung
@es
Clement Chung
@nl
type
label
Clement Chung
@ast
Clement Chung
@en
Clement Chung
@es
Clement Chung
@nl
prefLabel
Clement Chung
@ast
Clement Chung
@en
Clement Chung
@es
Clement Chung
@nl
P1153
56013912300
P31
P496
0000-0002-7189-6612